Navrogen Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 4

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $542K

  • Investors
  • 3

Navrogen General Information

Description

Developer of biopharmaceutical technology designed to offer targeted treatment of cancer. The company's technology identifies several tumor-produced proteins that can suppress a patient's endogenous humoral immune response against cancer cells and suppress the therapeutic efficacy of an antibody-based drug, enabling physicians to discover and assemble a database of tumor types that can overcome their immunosuppressive effects.

Contact Information

Website
www.navrogen.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 1837 University Circle
  • Science Center Room 218
  • Cheyney, PA 19319
  • United States
+1 (610)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 1837 University Circle
  • Science Center Room 218
  • Cheyney, PA 19319
  • United States
+1 (610)

Navrogen Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Navrogen Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Later Stage VC 27-Jun-2024 $542K Completed Clinical Trials - General
1. Seed Round 03-Mar-2023 Completed Clinical Trials - General
To view Navrogen’s complete valuation and funding history, request access »

Navrogen Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Seed
To view Navrogen’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Navrogen Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of biopharmaceutical technology designed to offer targeted treatment of cancer. The company's technology ident
Drug Discovery
Cheyney, PA
4 As of 2026

Hamilton, Canada
 

Melbourne, Australia
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Navrogen Competitors (10)

One of Navrogen’s 10 competitors is Triumvira, a Venture Capital-Backed company based in Hamilton, Canada.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Triumvira Venture Capital-Backed Hamilton, Canada
Mesoblast Corporation Melbourne, Australia
Gilead Formerly VC-backed Foster City, CA
Pyxis Oncology Formerly VC-backed Boston, MA
Genetix Biotherapeutics Private Equity-Backed Somerville, MA
You’re viewing 5 of 10 competitors. Get the full list »

Navrogen Patents

  • 33

    Total Documents Applications and Grants

  • Total Patents Families

  • 11

    Granted

  • 14

    Pending

  • Expiring in next 12 mo

Navrogen Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4573127-A1 Fc-engineered monoclonal antibodies refractory to tumor immunosuppressive icam-1/cd54 Pending 15-Aug-2022
EP-4573127-A4 Fc-engineered monoclonal antibodies refractory to tumor immunosuppressive icam-1/cd54 Pending 15-Aug-2022
US-20260098858-A1 Fc-engineered monoclonal antibodies refractory to tumor immunosuppressive icam-1/cd54 Pending 15-Aug-2022
WO-2024040024-A1 Fc-engineered monoclonal antibodies refractory to tumor immunosuppressive icam-1/cd54 Inactive 15-Aug-2022
EP-4539853-A1 Humoral immune activators for the treatment of humoral immunosuppressed pathologies, cancer and infectious disease and humoral immune suppressors for the treatment of inflammatory diseases Pending 15-Jun-2022 A61K31/58
To view Navrogen’s complete patent history, request access »

Navrogen Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Navrogen Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
Angel (individual) Minority
Ben Franklin Technology Partners of Southeastern Pennsylvania Accelerator/Incubator Minority
Tellus BioVentures Venture Capital Minority
To view Navrogen’s complete investors history, request access »

Ready to get started?

Request a free trial

Navrogen FAQs

  • When was Navrogen founded?

    Navrogen was founded in 2017.

  • Where is Navrogen headquartered?

    Navrogen is headquartered in Cheyney, PA.

  • What is the size of Navrogen?

    Navrogen has 4 total employees.

  • What industry is Navrogen in?

    Navrogen’s primary industry is Drug Discovery.

  • Is Navrogen a private or public company?

    Navrogen is a Private company.

  • What is Navrogen’s current revenue?

    The current revenue for Navrogen is .

  • How much funding has Navrogen raised over time?

    Navrogen has raised $9.6M.

  • Who are Navrogen’s investors?

    , Ben Franklin Technology Partners of Southeastern Pennsylvania, and Tellus BioVentures have invested in Navrogen.

  • Who are Navrogen’s competitors?

    Triumvira, Mesoblast, Gilead, Pyxis Oncology, and Genetix Biotherapeutics are some of the 10 competitors of Navrogen.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process